Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Significant progress has been made in prospectively designing molecules using the central nervous system multiparameter optimization (CNS MPO) desirability tool, as evidenced by the analysis reported herein of a second wave of drug candidates that originated after the development and implementation of this tool. This simple-to-use design algorithm has expanded design space for CNS candidates and has further demonstrated the advantages of utilizing a flexible, multiparameter approach in drug discovery rather than individual parameters and hard cutoffs of physicochemical properties. The CNS MPO tool has helped to increase the percentage of compounds nominated for clinical development that exhibit alignment of ADME attributes, cross the blood-brain barrier, and reside in lower-risk safety space (low ClogP and high TPSA). The use of this tool has played a role in reducing the number of compounds submitted to exploratory toxicity studies and increasing the survival of our drug candidates through regulatory toxicology into First in Human studies. Overall, the CNS MPO algorithm has helped to improve the prioritization of design ideas and the quality of the compounds nominated for clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, A11 scores 4.8 out of 6 on the central nervous system multiparameter optimization (CNS MPO; Wager et al., 2016) desirability index, indicating favorable structural properties for CNS drug development (Fig. S4 d).”
From A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation (2023) · cites this paper as Wager et al., 2016
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, A11 scores 4.8 out of 6 on the central nervous system multiparameter optimization (CNS MPO; Wager et al., 2016) desirability index, indicating favorable structural properties for CNS drug development (Fig. S4 d).”
From A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation (2023) · cites this paper as Wager et al., 2016
In the citing paper
“Clearly, molecular weight is a physicochemical parameter fundamental for CNS penetration and for the overall profile of drugs against neurodegenerative diseases.103,104”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantifying the chemical beauty of drugs
Bickerton, G. R., Paolini, G. V., Besnard, J., Muresan, S., & Hopkins, A. L. (2012) · Nature Chemistry · doi:10.1038/nchem.1243 · Cited by 2,242
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100008c · Cited by 1,063
Self-citationPhysiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Self-citationCNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure
Rankovic, Z. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501535r · Cited by 548
Wager, T. T., Chandrasekaran, R. Y., Hou, X., Troutman, M. D., Verhoest, P. R., Villalobos, A., & Will, Y. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100007x · Cited by 477
Self-citationGhose, A. K., Herbertz, T., Hudkins, R. L., Dorsey, B. D., & Mallamo, J. P. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200100h · Cited by 447
Feng, B., Mills, J. B., Davidson, R. E., Mireles, R. J., Janiszewski, J. S., Troutman, M. D., & de Morais, S. M. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017434 · Cited by 440
Development of a new permeability assay using low‐efflux MDCKII cells
Di, L., Whitney‐Pickett, C., Umland, J. P., Zhang, H., Zhang, X., Gebhard, D. F., Lai, Y., Federico, J. J., Davidson, R. E., Smith, R., et al. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22674 · Cited by 313
Hosea, N. A., Collard, W. T., Cole, S., Maurer, T. S., Fang, R. X., Jones, H., Kakar, S. M., Nakai, Y., Smith, B. J., Webster, R., et al. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009333209 · Cited by 300
Ertl, P. (2007) · Methods and principles in medicinal chemistry · doi:10.1002/9783527621286.ch5 · Cited by 75
Research works printed but not linked: 1
- Harrington, E. C., Jr. (1965) The desirability function. Indust. Qual. Control 21, 494-498.
Cited by
Items 401–500 of 746
PROTACs for central nervous system disorders: challenges and opportunities
Zheng, N., Shao, J., Xiong, B., Wei, Y., Wang, X., Zhou, Y., Song, Z., Zhang, A., Xu, C., Zhao, Q., et al. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118703 · Cited by 4
Nicolov, M. F., Dușe, A. O., Jurj, E.-D., Colibăşanu, D., Voicu, A., Watz, C. G., Voicu, M., & Udrescu, L. (2026) · Pharmaceuticals · doi:10.3390/ph19060840 · Cited by 4
“…permeability and clearance-related trends, but should not be interpreted as a definitive representation of clinical pharmacokinetic behavior, particularly for compounds whose exposure is shaped by solubility, formulation, pH-dependent stability, or transporter-mediated processes [6,20,26,28,52].”
Yao, G., Parris, M. R., Kuo, W. C., Pörzgen, P., Castillo, B., Mason, E. S., Chinchilla, A., Huang, J., Suzuki, S., Ross, R., et al. (2024) · Journal of Natural Products · doi:10.1021/acs.jnatprod.3c00942 · Cited by 4
Hussein, E. M., Moussa, Z., Obaid, R. J., Abd‐El‐Aziz, A., Altass, H. M., Elbanna, K., Abulreesh, H. H., Almalki, M., Banerjee, A., Chattopadhyay, A., et al. (2024) · ChemistrySelect · doi:10.1002/slct.202401009 · Cited by 4
Jakova, E., Aigbogun, O. P., Moutaoufik, M. T., Allen, K. J. H., Munir, O., Brown, D., Taghibiglou, C., Babu, M., Phenix, C. P., Krol, E. S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179386 · Cited by 4
A Repurposed Drug Selection Pipeline to Identify CNS-Penetrant Drug Candidates for Glioblastoma
Ntafoulis, I., Koolen, S. L. W., van Tellingen, O., den Hollander, C. W. J., Sabel-Goedknegt, H., Dijkhuizen, S., Haeck, J. C., Reuvers, T. G. A., de Bruijn, P., van den Bosch, T. P. P., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17121687 · Cited by 4
Czopek, A., Byrtus, H., Góra, M., Rapacz, A., Sałat, K., Koczurkiewicz, P., Pękala, E., Obniska, J., & Kamiński, K. (2024) · ChemMedChem · doi:10.1002/cmdc.202400612 · Cited by 4
Design and synthesis of pyridopyrimidines targeting NEK6 kinase
Zardi, P., Righino, B., Pirolli, D., Gramanzini, M., Semeraro, A., Galano‐Frutos, J. J., Königs, A., Đorđević∞, L., Maggini, M., Buttarelli, M., et al. (2025) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2025.110391 · Cited by 4
Synthesis and SAR of novel GPR39 agonists and positive allosteric modulators
Burley, R., Hewer, R. C., Teall, M. R., Dickson, L., Ossola, B., Russell, S., Bender, C., Cheung, T., Powell, J., Xu, X., et al. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128607 · Cited by 4
Gáborová, M., Vágvölgyi, M., Tayeb, B. A., Minorics, R., Zupkó, I., Jurček, O., Béni, S., Kubínová, R., Balogh, G. T., & Hunyadi, A. (2024) · ACS Omega · doi:10.1021/acsomega.4c00800 · Cited by 4
Halogen Bonding Hot Spots as a Constraint in Virtual Screening: A Case Study of 5-HT7R
Kurczab, R. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00816 · Cited by 4
Engers, J. L., Baker, L. A., Chang, S., Luscombe, V. B., Rodriguez, A. L., Niswender, C. M., Cho, H. P., Bubser, M., Gray, A. T., Jones, C. K., et al. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00465 · Cited by 4
Shen, Z., Song, J., Wang, S., Tang, M., Yang, Y., Yu, M., Zhang, R., Zhou, H., & Jiang, G. (2024) · Gene · doi:10.1016/j.gene.2024.149084 · Cited by 4
Selective Mu-Opioid Receptor Imaging Using 18F-Labeled Carfentanils
Lee, S. J., Pearson, T. D., Dhaynaut, M., MacDonagh, A. C., Wey, H., Wilks, M. Q., Roth, B. L., Hooker, J. M., & Normandin, M. D. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02287 · Cited by 4
Singh, V., Wan, Y., Gao, Z., Ahmed, T. R., Wang, S.-Y., Chen, K., Samrat, S. K., Li, Z., Sinha, S. C., Gan, L., et al. (2026) · ACS Chemical Biology · doi:10.1021/acschembio.6c00369 · Cited by 4
New oxacycles on the block: benzodioxepinones via a Passerini reaction
Fragkiadakis, M., Zingiridis, M., Loukopoulos, E., & Neochoritis, C. G. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10502-9 · Cited by 4
Two-drug trick to target the brain blocks toxicity in the body
Wymann, M. P., & Borsari, C. (2022) · Nature · doi:10.1038/d41586-022-02892-5 · Cited by 4
Evaluation of thiadiazine-based PET radioligands for imaging the AMPA receptor
Chen, J., Ran, W., Huang, Y., Wei, J., Rong, J., Wei, H., Li, Y., Li, G., Chen, Z., Collier, L., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115842 · Cited by 4
Sun, H., Wang, Y., Shi, W., Yang, F., Tang, J., Pang, T., & Yu, L.-F. (2018) · RSC Advances · doi:10.1039/c8ra00072g · Cited by 4
Discovery of quinuclidine modulators of cellular progranulin
Lanter, J. C., Chen, A. Y.-P., Williamson, T. L., Koenig, G., Blain, J., & Burnett, D. A. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128209 · Cited by 4
Bartolo, N. D., Mortimer, N., Manter, M. A., Sanchez, N., Riley, M. M., O’Malley, T. T., & Hooker, J. M. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00607 · Cited by 4
Central Nervous System Multiparameter Optimization Desirability
Talevi, A. (2021) · Springer eBooks · doi:10.1007/978-3-030-51519-5_150-1 · Cited by 4
Attentive graph neural network models for the prediction of blood brain barrier permeabilityPreprint
Collins, J. W., Ebrahimkhani, M., Ramirez, D., Deiloff, J., Gonzalez, M., Abedi, M., Philippe-Venec, L., Cole, B. M., Moore, B., & Nwankwo, J. O. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.12.617907 · Cited by 4
“We adopted the approach described by Wager et al. 46 for scoring various molecular properties.”
MethodResultMolecular Generation for CNS Drug Discovery and Design
Chen, S., Luo, D., & Xue, W. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00095 · Cited by 4
Tang, H., Long, J., Ji, B., & Wang, J. (2025) · arXiv (Cornell University) · doi:10.48550/arxiv.2502.16446 · Cited by 4
Dahl, K., Johnström, P., Tóth, M., Bolin, M., Varnäs, K., Nakao, R., Takano, A., Meynaq, Y. K., Bayrakdarian, M., Cselényi, Z., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18020135 · Cited by 3
“This is a step towards the development of a PET radioligand for in vivo visualization of CCR2 binding in the human brain.”
Gupta, A., Verma, A., & Katiyar, K. (2025) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2025.2472401 · Cited by 3
“The CNS Multiparameter Optimisation (CNS MPO) tool was used to ADME attribute alignment and validation of lead phytochemicals (Wager et al., 2016).”
Liu, B., Christopoulos, A., Thal, D. M., Capuano, B., Valant, C., & Scammells, P. J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00678 · Cited by 3
Bioactive structures for inhibitors of Candida auris polymerase enzyme by artificial intelligence
Pinto, F. D. C. L., Cabongo, S. Q., Joao, P. F. B., Lima, M. P., Paiva, M. M. P. C., Madureira, J. M. C., Caluaco, B. J., Colares, R. P., Neto, M. M., dos Santos, H. S., et al. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2491301 · Cited by 3
de Oliveira, V. M., Roberto, C. H. A., da Rocha, M. N., Jucá, F. M., Marinho, M. M., dos Santos, H. S., & Marinho, E. S. (2025) · Discover Chemistry. · doi:10.1007/s44371-025-00287-9 · Cited by 3
“9c), indicating that they are highly permeable compounds in more selective biological membranes [61].”
InfluentialPusztai, G., Poszávácz, L., Vincze, A., Marton, A., Abdulhussein, A. Q., Halász, J., Dancsó, A., Simig, G., Balogh, G. T., & Volk, B. (2025) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.21.169 · Cited by 3
de Sousa, D. S., de Oliveira, V. M., Belarmino, A. B., Mendes, F. R. D. S., Marinho, M. M., & Marinho, G. S. (2025) · Total Chemistry · doi:10.1016/j.totche.2025.100020 · Cited by 3
Toward Brain NaV1.8 Imaging with [11C]Suzetrigine
Tokala, R., Pearson, T. D., Mair, B. A., Bricault, S., Wallace, R., Wey, H., Hooker, J. M., & Lee, S. J. (2025) · Pharmaceuticals · doi:10.3390/ph18121816 · Cited by 3
“Molecular descriptor analysis was performed to evaluate the physicochemical suitability of suzetrigine for CNS imaging [35,36,39].”
Jun, J., Choi, S., Moon, J., Oh, J., Kim, J., Park, H., Bhujbal, S. P., Park, K.-S., & Hah, J. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03011 · Cited by 3
Do Amino-Oxetanes Resemble Amides? A Matched Molecular Pairs Property and Structural Comparison
Ishikura, H., Begg, C. S., Rojas, J. J., Blagojevic, L., Smith, G. J., Luk, J., Croft, R. A., Romain, C., Choi, C., & Bull, J. A. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02614 · Cited by 3
da Silva, M. V. F., Silva, J., da Rocha, M. N., de Morais, S. M., & Marinho, E. S. (2026) · In Silico Pharmacology · doi:10.1007/s40203-026-00590-y · Cited by 3
“Wager et al. ( 2016 ) reported in their multiparametric optimization analysis that compounds more polar than drugs commonly approved as oral route drugs may present a moderate cell permeability ( P app in order of 10 − 6 cm/s) and low intrinsic hepatic clearance ( Cl int, u < 8.0 mL/min/kg), due to…”
InfluentialArtificial intelligence revolutionizing CNS drug discovery and development
Talukder, M. E. K., Islam, M. R., Ali, S., Zhou, J., & Bolinger, A. A. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104667 · Cited by 3
Novás, M., López, N. B., Santana, L., Uriarte, E. E., & Matos, M. J. (2026) · Molecules · doi:10.3390/molecules31132366 · Cited by 3
“Therefore, reducing the number of HBDs in a molecule can substantially lower the PSA, enhancing its potential to passively cross the BBB [23].”
Jakubiec, M., Abram, M., Zagaja, M. P., Andres‐Mach, M., Szala‐Rycaj, J., Latacz, G., Honkisz-Orzechowska, E., Mogilski, S., Kubacka, M., Szafarz, M., et al. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00013 · Cited by 3
Ence, C. C., Uddin, T., Borrel, J., Mittal, P., Xie, H., Zoller, J., Sharma, A., Comer, E. J., Schreiber, S. L., Melillo, B. N., et al. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00170 · Cited by 3
Siafis, S., Nomura, N., Schneider‐Thoma, J., Bighelli, I., Bannach‐Brown, A., Ramage, F. J., Tinsdeall, F., Mantas, I., Jauhar, S., Natesan, S., et al. (2024) · F1000Research · doi:10.12688/f1000research.155356.1 · Cited by 3
Song, Z., Li, Y., Dahl, K., Chaudhary, A. F., Sun, Z., Zhou, X. M., Chen, J., Gao, Y., Rong, J., Zhao, C., et al. (2024) · ChemBioChem · doi:10.1002/cbic.202400655 · Cited by 3
Jie, C. V. M. L., Delparente, A., Reichert, L., Albrecht, M., Atz, K., Schneider, G., Schibli, R., & Mu, L. (2025) · Chemistry - A European Journal · doi:10.1002/chem.202404517 · Cited by 3
Engers, J. L., Bollinger, S. R., Gregro, A. R., Capstick, R. A., Spearing, P. K., Long, M. F., Tarr, J. C., Watson, K. J., Chang, S., Luscombe, V. B., et al. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00277 · Cited by 3
Zhang, P., Taghavi, A., Abe, M., Aikawa, H., Akahori, Y., Chen, J. L., Tong, Y., Baisden, J. T., Cameron, M. D., Childs‐Disney, J. L., et al. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.5c00260 · Cited by 3
Alves, A. M. B., Romão, I. C., Souza, R. J., Marinho, E. S., Marinho, M. M., da Rocha, M. N., Canuto, K. M., de Menezes, J. E. S. A., Siqueira, S. M. C., & dos Santos, H. S. (2025) · ACS Omega · doi:10.1021/acsomega.5c04279 · Cited by 3
Tâm, N. M., Tran, L. H., Vo, Q. V., Pham, M. Q., & Phùng, H. T. T. (2023) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416523500242 · Cited by 3
Inhibition of N-type calcium channels by phenoxyaniline and sulfonamide analogues
Bispat, A. S., Cardoso, F. C., Hasan, M. M., Dongol, Y., Wilcox, R., Lewis, R. J., Duggan, P. J., & Tuck, K. L. (2024) · RSC Medicinal Chemistry · doi:10.1039/d3md00714f · Cited by 3
Childress, E. S., Capstick, R. A., Crocker, K. E., Ledyard, M. L., Bender, A. M., Maurer, M. A., Billard, N. B., Cho, H. P., Rodriguez, A. L., Niswender, C. M., et al. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00481 · Cited by 3
Qi, B., Guan, L., Tan, J., Li, G., Sun, Y., Zhang, Q., & Zou, Y. F. (2024) · Physical Chemistry Chemical Physics · doi:10.1039/d4cp03207a · Cited by 3
Lemos, C. G., da Silva, A. W., Maciel, J. B., Ferreira, M. K. A., da Rocha, M. N., Marinho, M. M., Marinho, E. S., Pinto, F. D. C. L., Loiola, O. D., Gomes, A. F. D. C., et al. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202402173 · Cited by 3
“A multi-parameter optimization (MPO) system developed by Wager et al. [33] and applied to a set of experimental data for drugs in clinical trials and drug candidates suggests that weakly basiccompounds(pKa < 8.0)thatareslightlylipophilic(log P < 3) and more polar than CNS agents, whose sum of the…”
InfluentialLima, I. K. C., Silva, J. B., Guedes, J. M., Ribeiro, M. A., Freire, V. N., Ayala, A. P., dos Santos, R. C. R., Silva, B. P. E., Marinho, E. S., da Rocha, M. N., et al. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.141181 · Cited by 3
Presser, A., Blaser, G., Pferschy‐Wenzig, E., Kaiser, M., Mäser, P., & Schuehly, W. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052114 · Cited by 3
“All reagents and solvents were obtained from Merck and Fluorochem Ltd. ) Moisture-sensitive reactions were performed under an inert argon Moisture-sensitive reactions were performed under an inert argon atmosphere. atmosphere Each reaction was monitored by TLC on Merck TLC plates (silica Each…”
Guan, D., Lakmal, H. H. C., Bender, B. N., Rahman, M. T., Gay, E. A., Barrus, D. G., Mosera, A. M., Kerr, A. T., Besheer, J., & Jin, C. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00361 · Cited by 3
Soda, A. K., Huang, T., Zhou, W., Chen, H., Jiang, H., Jadhav, S. B., Xing, Z., Yu, Y., Tian, L., Wong, D. F., et al. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118218 · Cited by 3
Lazić, A., Mandic, Z., Valentić, N. V., Uščumlić, G., & Trišović, N. P. (2019) · Hemijska industrija · doi:10.2298/hemind181203007l · Cited by 3
“[41] Wager TT, Hou X, Verhoest PR, Villalobos A.”
BackgroundDrug Delivery to Primary and Metastatic Brain Tumors: Challenges and Opportunities
Talele, S., Mohammad, A. S., Schulz, J., Bauer, B., Hartz, A. M. S., Sarkaria, J. N., & Elmquist, W. F. (2022) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-88773-5_24 · Cited by 3
Glioblastoma - Current Evidence
Agrawal, A., & Kunwar, D. S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100846 · Cited by 3
Quinney, S. K., Kandasamy, M., Oblak, A. L., Onos, K. D., Sasner, M., Greenwood, A. K., Woo, K., Rizzo, S. J. S., & Territo, P. R. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13108 · Cited by 3
Liow, J., Morse, C. L., Lu, S., Frankland, M. P., Tye, G. L., Zoghbi, S. S., Gladding, R. L., Shaik, A. B., Innis, R. B., Newman, A. H., et al. (2018) · Molecules · doi:10.3390/molecules23112737 · Cited by 3
Horne, R. I., Possenti, A., Chia, S., Brotzakis, Z. F., Staats, R., Nowinska, M., & Vendruscolo, M. (2022) · Research Square · doi:10.21203/rs.3.rs-1236129/v1 · Cited by 3
Gardner, L., Rossi, J., Armstrong, B. A., Muse, M., LaVeck, A., Blevins, M. A., Zhang, L., Ford, H. L., Zhao, R., & Wang, X. (2024) · ChemMedChem · doi:10.1002/cmdc.202400179 · Cited by 2
Huang, B., Ma, H., Pagare, P. P., Li, M., Mendez, R. E., Gillespie, J. C., Poklis, J. L., Halquist, M. S., Stevens, D. L., Dewey, W. L., et al. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00593 · Cited by 2
Mendes, J. L., da Silva, L. E., do Amaral, W., Confortin, C., Ferreira, M. K. A., Marinho, M. M., Mendes, F. R. D. S., Marinho, E. S., Romão, I. C., Magalhães, E. P., et al. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202403357 · Cited by 2
Predicting the Brain-To-Plasma Unbound Partition Coefficient of Compounds via Formula-Guided Network
Zou, Y., Yuan, H., Guo, Z., Guo, T., Fu, Z., Wang, R., Xu, D., Wang, Q., Wang, T., & Chen, L. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c00590 · Cited by 2
Song, Z., Li, Y., Dahl, K., Sun, Z., Chen, J., Zhou, X. M., Gao, Y., Rong, J., Zhao, C., Yuan, K. Y., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02924 · Cited by 2
Wang, Y., Dai, C., & Lei, X. (2025) · Pharmaceuticals · doi:10.3390/ph18081227 · Cited by 2
Zhu, M., Xie, X.-P., Wang, S., Zhang, X. X., Xie, Z., Duan, Y., Zhao, Z., & Liao, C. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118080 · Cited by 2
Pinheiro, N. A. P., Romão, I. C., Alves, A. M. B., Siqueira, S. M. C., de Menezes, J. E. S. A., Marinho, E. S., Ferreira, M. K. A., Marinho, M. M., Magalhães, H. D. S., Gomes, A. F. D. C., et al. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202501738 · Cited by 2
“According to Wager et al. [27] and Sun et al. [28], within the CNS Mul-tiparameter Optimization (MPO) framework, compounds with low lipophilicity (log P ≤ 3), higher molecular weight (MW 200–500 g/mol), and greater polarity (topological polar surface area [TPSA] between 40 and 90 Å 2 ) tend to…”
Gomes, A. O. C. V., Lúcio, F. N. M., da Rocha, M. N., de Oliveira, V. M., Roberto, C. H. A., Marinho, M. M., dos Santos, H. S., de Lima‐Neto, P., & Marinho, E. S. (2025) · Journal of Molecular Modeling · doi:10.1007/s00894-025-06590-7 · Cited by 2
“According to Wager et al. (2016) [91], lead compounds are weak bases (pKa < 8.0) with low lipophilicity at physiological pH (ClogD at pH 7.4 ≤ 4.0) that are more polar than compounds toxic to the CNS (TPSA 40–90 Å 2 ), within an MW range of 200–360 g/mol, present a better alignment between in vitro…”
InfluentialCNS penetrant TEAD1,2,4 inhibitor MSC-4070 derived from phenotypic screening hit optimization
Heinrich, T., Petersson, C., Gunera, J., Gambardella, A., Schwarz, D., Garg, S., Schilke, H., Weitzel, T., Kolb, C., Anlauf, U., et al. (2026) · RSC Medicinal Chemistry · doi:10.1039/d5md00928f · Cited by 2
Su, Q., Ye, Z., Han, C., Xiao, G., Chen, J., Chen, H., Wang, Z., Huang, S., Wang, L., Peng, G., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01791 · Cited by 2
da Silva, M. V. F., Silva, J., de Oliveira, V. M., da Rocha, M. N., de Morais, S. M., & Marinho, E. S. (2026) · Archives of Microbiology · doi:10.1007/s00203-026-04814-9 · Cited by 2
“These findings suggest that the compound possesses the capacity to permeate even the most selective biological membranes (Ma et al. 2005; Wager et al. 2016).”
Zhi, Y., Ma, D., Fan, S., Zhou, W., li, Y., Zhou, Y., Che, H., Yang, G., Sun, M., Yao, J., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03239 · Cited by 2
Gomes, A. O. C. V., de Sousa, D. S., Lúcio, F. N. M., & Marinho, E. S. (2026) · Journal of the Iranian Chemical Society · doi:10.1007/s13738-026-03449-3 · Cited by 2
Cottrell, K. M., Briggs, K. J., Tsai, A., Liang, C., McCarren, P. R., Whittington, D. A., Zhang, M., Zhang, W., Huang, A., Andersen, J. N., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00035 · Cited by 2
Persico, M., Micoli, A., Salmaso, V., Cianciulli, A., Moro, S., Spalluto, G., Buccioni, M., Marucci, G., Volpini, R., Pozzan, A., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00231 · Cited by 2
“51 Moreover, on a second iteration following the initial results, we included interaction-specific constraints to interact with a specific protein residue (Asn253) as a pure docking-driven score could miss this important interaction.”
Masri, H. M. (2026) · Chemistry · doi:10.3390/chemistry8070093 · Cited by 2
“A representative optimized coumarin MTDL with MW ~420 D, logP 2.8, TPSA 72 Å 2 , and PAMPA-BBB Pe ~5 × 10 − 6 cm/s has an estimated CNS multiparameter optimization (MPO) score of ~4.2 on the Wager scale, which is within the “acceptable” CNS range of ≥ 4.0 [64].”
InfluentialLi, Y., Glotfelty, E. J., Parekh, P., Batsaikhan, B., Luo, W., Jackson, S. N., Harvey, B. K., & Greig, N. H. (2026) · Cells · doi:10.3390/cells15141301 · Cited by 2
“As an initial estimate of the CNS penetration potential of orforglipron, we calculated its standard Central Nervous System Multiparameter Optimization (CNS MPO) desirability score [78], which equaled 1.8.”
InfluentialMulti-objective optimization in the context of generative chemistry
Torren-Peraire, P., Schneider, N., Rodríguez-Pérez, R., Fairhurst, R. A., & Lanini, J. (2026) · Nature Communications · doi:10.1038/s41467-026-77324-3 · Cited by 3
Langer, G., Scott, J., Lind, C., Otto, C., Bothe, U., Laux‐Biehlmann, A., Müller, J., le Roy, B., Irlbacher, H., Nowak‐Reppel, K., et al. (2023) · Molecular Pharmacology · doi:10.1124/molpharm.122.000662 · Cited by 2
“…= 2.40 µM, Muscarinic M2: IC50 = 2.61 µM, Cannabinoid CB1: IC50 = 4.16 µM. c CNS MPO = Central nervous system multiparameter optimization desirability tool (Wager et al., 2016). d BBB MPO = Blood Brain Barrier multiparameter optimization desirability tool (Gupta et al., 2019). e Calculated…”
BackgroundInfluentialHaque, A., Alenezi, K. M., Rasheed, M. S. M. A., Rahman, M. A., Anwar, S., Ahamad, S., & Gupta, D. K. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1517504 · Cited by 2
“Besides, it also aids researchers in guiding the design of new molecules with desired characteristics and establishing correlations with biological outcomes (Wager et al., 2016).”
Tanaka, Y. (2025) · Journal of Mass Spectrometry · doi:10.1002/jms.5135 · Cited by 2
Morsy, A. (2021) · DigitalCommons@UNMC · Cited by 2
The LeadSampler (LS‐1) Sample Delivery System
Kapinos, B., & Janiszewski, J. S. (2023) · Wiley eBooks · doi:10.1002/9781119678496.ch2 · Cited by 2
Ogata, A., Ikenuma, H., Abe, J., Yamada, T., Hattori, S., Ichise, M., Suzuki, M., Kato, T., & Kimura, Y. (2023) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-023-09171-1 · Cited by 2
“Importantly, MNS is expected to have a high brain penetration based on the favorable parameter values calculated by the multi-parameters optimization (MPO) [13].”
MethodDeveloping Low Molecular Weight PET and SPECT Imaging Agents
Xue, L., Jie, C. V. M. L., Desrayaud, S., & Auberson, Y. P. (2024) · ChemMedChem · doi:10.1002/cmdc.202400094 · Cited by 2
Deep convolutional neural network-based identification and biological evaluation of MAO-B inhibitors
Kashyap, K., Bhati, G., Ahmed, S., & Siddiqi, M. I. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.136438 · Cited by 2
Does the drug enter the brain? If so, how much?
Hammarlund‐Udenaes, M. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2024.100043 · Cited by 2
Silva, J., da Rocha, M. N., de Oliveira, V. M., Roberto, C. H. A., Lúcio, F. N. M., Marinho, M. M., dos Santos, H. S., & Marinho, E. S. (2025) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-025-00783-w · Cited by 2
“Wager and coworkers (2016) [22] observed that among a group of drugs, drug candidates, and drugs in experimental stages, substances residing in a physicochemical space formed by high lipophilicity and low polarity (AlogP > 3 and TPSA ≤ 75 Å 2 ) showed CNS activity with high apparent cell…”
Poulter, S., Austin, N. E., Watson, S. P., Bucknell, S. J., O’Brien, A., Tolonen, A., Lassila, T., Stott, L. A., Mead, A. N., & MacSweeney, C. P. (2025) · Xenobiotica · doi:10.1080/00498254.2025.2501593 · Cited by 2
“…low molecular weight (390.3 Daltons), modest polar surface area (PSA) of 59.8 Å 2 and low number of hydrogen bond acceptors (5) and donors (1) place it in accepted physico-chemical space for good oral absorption and CNS druggability, supported by a CNS MPO score of 5.0 (Wager et al. 2016).”
InfluentialMartino, R. M. C. D., Russo, D., Penna, I., Demuro, S., Vedove, A. D., Spagnuolo, R., Ottonello, G., Bertozzi, S. M., Summa, M., Desantis, J., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117899 · Cited by 2
Ingraham, C. H., Polanía-Villanueva, D., Macaluso, A., Tramuta, A., Vittori, C., Hunter, J., Rak, M., Claudio, P. P., Ibrahim, M. A., Valle, L. D., et al. (2025) · Journal of Cellular Physiology · doi:10.1002/jcp.70062 · Cited by 2
“…predictions from central nervous system – multiparameter optimization (CNS ‐ MPO), Blood ‐ Brain Barrier Score (BBB_SCORE) (Ingraham et al. 2023; Wager et al. 2010, 2016), and calculated cardiac toxicity that involves inhibition of the cardiac potassium channel, human ether ‐ go ‐ go ‐…”
InfluentialFrandsen, J. R. (2020) · DigitalCommons@UNMC · Cited by 2
Targeted Protein Degradation as a Therapeutic Strategy in Neurodegenerative Diseases
Ferguson, F. M. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch7 · Cited by 2
Jennings, L. K. (2018) · Griffith Research Online · doi:10.25904/1912/722 · Cited by 2
EVALUATING NATURAL PRODUCT LIBRARIES WITH EMPHASIS ON IN VITRO PERMEABILITY WORKFLOWS
Kirk, R. D. (2021) · Digital Commons - URI (University of Rhode Island) · doi:10.23860/diss-kirk-riley-2021 · Cited by 2
Unbiased preclinical phenotyping reveals neuroprotective properties of pioglitazonePreprint
Harding, E. C., Chen, H. C., Shepilov, D., Zhang, S., Rowley, C., Mali, I. D., Chen, J., Stewart, N. M., Swinden, D., Washer, S. J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.30.610328 · Cited by 2
“Around 1000 of these have the chemical properties associated with penetration of the blood brain barrier (BBB) making them potentially suitable for targeting central nervous system (CNS) disorders (D. Segall, 2012; Wager et al. , 2016).”
BackgroundMethodInfluentialSong, Z., Li, Y., Feng, S., Chen, J., Zhou, X. M., Zhang, Z., Sun, Z., Rong, J., Zhao, C., Chaudhary, A. F., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.16.633384 · Cited by 2
Montoya, M. C., & Krysan, D. J. (2020) · UR Research (University of Rochester) · Cited by 2
Metadata
- Authors
- Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A.
- Affiliations
- Pfizer (United States) (US)
- Corresponding author
- Wager, Travis T.
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-03-18
- Volume
- 7
- Issue
- 6
- Pages
- 767-775
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W2300160852
- Cited by
- 653
- References
- 13
- Citations by year
- 2026: 104 · 2025: 121 · 2024: 103 · 2023: 75 · 2022: 72 · 2021: 45 · 2020: 37 · 2019: 32 · 2018: 40 · 2017: 19 · 2016: 5
- FWCI
- 30.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- ACS Chemical Neuroscience (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- desirability function, drug candidate design, ADME properties, blood-brain barrier permeability, ClogP, topological polar surface area, drug safety, drug discovery
- MeSH terms
- Algorithms, Animals, Biological Transport, Blood-Brain Barrier, Central Nervous System, Humans, Permeability, Drug Design, ATP Binding Cassette Transporter, Subfamily B, Member 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.